GERN

Business Context and Reporting Period

Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1997
Business Overview: Geron is a biopharmaceutical company focused on discovering and developing therapeutic and diagnostic products based on the biological mechanisms underlying cancer and age-related diseases, specifically targeting telomerase and telomere biology. The company is in an early stage of development with no marketed therapeutic products.

Key Financial Metrics

Cash Flow (Nine Months Ended Sep 30, 1997):
- Net cash used in operating activities: $(5,850) thousand
- Net cash used in investing activities: $(7,746) thousand
- Net cash provided by financing activities: $6,147 thousand
- Net decrease in cash and cash equivalents: $(7,449) thousand

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased to $2.2 million for the quarter (from $1.5 million in 1996) and $4.5 million for the nine-month period (from $4.4 million in 1996). This increase is driven by new collaborative agreements with Pharmacia & Upjohn and continued funding from Kyowa Hakko.
• Net Loss Improvement (Quarterly): Net loss decreased to $2.0 million for the quarter compared to $2.7 million in the prior year quarter, primarily due to higher revenue recognition offsetting increased operating expenses.
• Net Loss Increase (Year-to-Date): Net loss increased to $8.2 million for the nine-month period compared to $7.6 million in the prior year, driven by higher operating expenses.
• Operating Expenses: Research and development expenses rose to $11.3 million for the nine months (from $10.5 million in 1996) due to expanded patent activities and support for outside collaborators. General and administrative expenses increased slightly to $2.4 million.
• Liquidity: Cash and short-term investments remained relatively stable at approximately $24.0 million as of September 30, 1997, compared to $24.3 million at year-end 1996, despite a net cash decrease from operations, due to equity sales and research funding.

Guidance, Outlook, and Risks

Management Commentary and Outlook:
- The company estimates existing capital resources, combined with payments from Pharmacia & Upjohn and Kyowa Hakko, interest income, and grant funding, will be sufficient to fund operations through 1998.
- Geron does not expect to receive significant revenues from therapeutic products for a period of years. Current revenues are derived primarily from research support payments under collaborative agreements.
- Recent milestones include the issuance of three U.S. patents related to telomerase, the cloning of the human telomerase catalytic protein, and the receipt of a $750,000 Phase II SBIR grant from the NIH.

Key Risks and Contingencies:
- Technological Uncertainty: No assurance that research will lead to marketable products; significant preclinical and clinical testing required.
- Dependence on Collaborators: The company relies heavily on Pharmacia & Upjohn and Kyowa Hakko for funding, development, and commercialization. Failure of these partners to perform could materially adversely affect the company.
- Capital Needs: Substantial additional capital will be required in future periods. Failure to secure funding could force delays or elimination of research programs.
- Intellectual Property: Risks regarding patent validity, enforcement, and potential infringement claims, including a specific potential dispute regarding a licensing agreement with The Johns Hopkins University.
- Regulatory and Market Risks: Uncertainty regarding FDA approvals, market acceptance, and reimbursement policies.

Investor Verification Checklist

• Collaborative Agreement Terms: Verify the specific payment schedules and expiration dates of the agreements with Pharmacia & Upjohn (expires Jan 2000) and Kyowa Hakko (expires April 1998).
• Cash Runway: Confirm the sufficiency of the $24 million in liquid assets to sustain operations through 1998 given the high burn rate (approx. $5.9 million cash used in operations for nine months).
• Intellectual Property Status: Review the status of the 44+ pending U.S. patent applications and the potential impact of the third-party claim regarding the Johns Hopkins University agreement.
• Revenue Recognition Policy: Understand that revenues are recognized as R&D costs are incurred under collaborative agreements, meaning revenue is tied directly to spending rather than product sales.
• Future Financing Plans: Assess the likelihood and terms of future equity financings or strategic partnerships required post-1998.